So far, Roche’s Tecentriq hasn’t been able to find a piece of the lung cancer market to call its own. But that may change after its latest trial win.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,